glimepiride (Amarel)

10/01/1998 - "The safety and efficacy of glimepiride have been confirmed in studies involving more than 5000 patients with type 2 diabetes. "
12/01/2012 - "Therefore, glimepiride nanosuspensions can be expected to gain considerable attention in the treatment of type 2 diabetes mellitus due to its improved therapeutic activity."
01/01/2003 - "These results indicate that once-daily glimepiride plus diet/exercise was effective in Mexican Americans with type 2 diabetes whose disease was inadequately controlled with diet/exercise alone. "
04/01/2014 - "Twenty-six patients with poorly controlled type 2 diabetes currently taking high-dose glimepiride (≥ 2 mg/day) were enrolled in the study. "
01/01/2004 - "This study was conducted to examine the influence of glimepiride on insulin secretion and sensitivity in patients with type 2 diabetes mellitus (DM) of recent onset. "

09/01/2018 - "We aimed to study the efficacy of glimepiride in a patient with type A insulin resistance syndrome. "
02/01/2005 - "Insulin resistance determines efficacy of glimepiride in Type 2 diabetic patients not well controlled by diet alone."
03/11/2005 - "Recent clinical studies showed glimepiride to enhance insulin sensitivity. "
07/01/2001 - "Additionally, it is confirmed by basic studies that part of the glimepiride effect is attributable to improving insulin sensitivity. "
09/01/2018 - "Treatment with glimepiride did not improve insulin sensitivity in a patient with type A insulin resistance syndrome carrying Ile1143Phe heterozygous mutation in the INSR gene. "

05/04/2022 - "Glimepiride is used to treat type II diabetes but is associated with side effects, like lower half-life, faster elimination, and hypoglycemia. "
07/01/2021 - "Mild hypoglycemia was reported with glimepiride in five patients. "
05/01/2016 - "Also, compared with baseline, a significant increase in perceived frequency of hypoglycemia was observed in the glimepiride treatment group at all visits. "
03/27/2015 - "All but one patient no longer experienced hypoglycemia after discontinuing glimepiride. "
12/01/2014 - "The analysis indicates that the previously reported results are not driven by high doses of glimepiride and points to interesting differences among patients regarding the susceptibility to hypoglycemia with sulfonylureas."

03/01/2015 - "At baseline, overall mean age was 58.5 years, body weight 68.1 kg, duration of diabetes 6.9 years and daily glimepiride dose 3.3 mg. "
01/01/2014 - "CANA 100 and 300 mg reduced body weight by 3.7 and 4.0 kg, respectively compared to a 0.7 kg increase with glimepiride. "
11/01/2011 - "The second and third subgroups were orally administered 0.1 mg kg(-1) body weight/day glimepiride and 250 mg kg(-1) body weight/day Nerium oleander, respectively for 4 weeks. "
04/01/2021 - "Daily oral administration of rats with extracts (HALE and EALE) and standard drug (Glimepiride, 5 mg/kg), reduced elevated BGL significantly (p < 0.001), and body weight was regained in diabetic rats. "
01/01/2016 - "Body weight did not change in either of the two groups, and one case of hypoglycemia was observed in the glimepiride group. "

12/01/2015 - "Weight gain was associated with glimepiride but it was non-significant (p=0.08). "
01/01/2003 - "More weight gain was seen with glimepiride compared with placebo. "
01/01/2012 - "In clinical studies, glimepiride was generally associated with lower risk of hypoglycemia and less weight gain compared to other sulfonylureas. "
03/01/2003 - "In clinical studies, glimepiride was generally associated with a lower risk of hypoglycemia and less weight gain than other SUs. "
07/01/2001 - "Outside of Japan, several clinical studies have demonstrated that glimepiride shows less hypoglycemia and no weight gain. "